COTA and Guardant Health Collaborate to Enhance Cancer Treatments
COTA Inc., a frontrunner in real-world data analytics for oncology, has forged an important partnership with Guardant Health Inc. This collaboration aims to leverage both companies' extensive databases to propel research into cancer therapies.
Understanding Clinicogenomic Data
As part of their partnership, COTA and Guardant Health will provide researchers access to a wealth of clinicogenomic data. This type of data combines genomic profiles with clinical outcomes, enabling scientists to delve deeper into the connections between molecular biomarkers and treatment decisions.
The Value of Real-World Data
Real-world data is vital for oncology researchers. With COTA's research-grade electronic health records and Guardant's advanced clinicogenomic testing, researchers can assess how different treatments perform across diverse populations. This insight helps to map out the journey of cancer patients, allowing scientists to optimize drug development and care strategies.
The Drug Development Challenge
The road to bringing a new cancer therapy to market is long and complex, often taking over a decade. Current statistics reveal that around 97% of clinical trials for cancer drugs fail. This alarming rate has prompted companies in the life sciences sector to prioritize the integration of diverse data types, including clinicogenomics.
Facilitating Drug Discovery
By accessing multi-modal datasets, biopharmaceutical developers can explore how different patient demographics respond to treatments. This information aids in biomarker discovery, refines clinical trials, speeds up regulatory approvals, and ultimately helps to deliver life-saving therapies to the market more rapidly.
Advancing Precision Medicine
Craig Eagle, MD, the chief medical officer of Guardant Health, emphasized the significance of real-world data partnerships. By correlating tumor biology and treatment responses with patient outcomes, this alliance aims to hasten the discovery of innovative biomarker-based therapies. This not only enhances efficiency but also makes the drug development process more cost-effective.
Combining Forces for Broader Insights
This partnership seamlessly merges Guardant’s extensive longitudinal testing datasets, which track the disease from initial profiling to therapy response monitoring, with COTA’s comprehensive patient journey data. Together, they provide a larger, more diverse data pool, particularly focusing on solid tumors such as lung, breast, and colorectal cancers.
About COTA, Inc.
COTA, founded by oncologists, is dedicated to reshaping cancer care with a patient-first approach using real-world data. Their innovative methods bridge complex patient data, ensuring high-quality information comes from top cancer centers. Partnering with various life sciences organizations, COTA aims to streamline the cancer care pathway for all patients.
About Guardant Health
Guardant Health focuses on precision oncology, utilizing blood and tissue tests to deliver crucial insights that transform patient care. Their commitment to combating cancer drives their goal of making sure every individual has access to effective cancer therapies through their advanced analytics and testing solutions.
Frequently Asked Questions
What is the main goal of the COTA and Guardant Health partnership?
The partnership seeks to enhance cancer therapy research by providing biopharmaceutical researchers access to combined clinicogenomic data and real-world health records.
How does clinicogenomic data benefit research?
Clinicogenomic data allows researchers to study patient genomic profiles alongside treatment outcomes, facilitating the development of targeted therapies.
Why is real-world data important in oncology?
Real-world data provides insights into patient responses to treatments, essential for optimizing drug development and personalizing cancer care.
What challenges do biopharmaceutical organizations face in drug development?
A significant challenge is the high failure rate of clinical trials, with many not translating into viable cancer therapies.
How do COTA’s and Guardant’s data work together?
By integrating their datasets, they create a broader information spectrum that can lead to better insights into therapy efficacy across various cancer types.
